Education
About Us
Working with TipRanks
Follow Us
Indaptus Therapeutics, Inc. (INDP)
:INDP
INDP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.48 - $58.25
Previous CloseN/A
Volume47.54K
Average Volume (3M)45.69K
Market Cap
$3.22M
Enterprise Value$6.43M
Total Cash (Recent Filing)$6.16M
Total Debt (Recent Filing)$34.37K
Price to Earnings (P/E)―
Beta2.15
Next Earnings
Nov 18, 2025EPS Estimate
-4.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9.09
Shares Outstanding1,106,529
10 Day Avg. Volume120,756
30 Day Avg. Volume45,686
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap2.00
Enterprise Value/Revenue4.38K
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.38
Forecast
1Y Price Target
$25.00Price Target Upside829.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Clinical Supply AgreementIndaptus signed a clinical supply agreement with BeiGene for its PD-1, tislelizumab, which could enhance the study by potentially combining treatments.
Clinical Trial ProgressThe combination study of Decoy and tislelizumab is ongoing, with positive safety results so far, which is promising for the treatment of solid tumors.
Safety ProfileDecoy therapy uses a nonpathogenic strain of bacteria, reducing endotoxin levels significantly, which enhances its safety profile.
Bears Say
Capital RequirementsIndaptus will need to raise additional capital to continue the clinical development of its Decoy immune therapy.
Financial ChallengesThe price target for Indaptus stock has been lowered due to expected dilution from future capital raises and recent financing activities.
Net Loss And Cash PositionIndaptus reported a net loss of ($4.5M) and ended the period with $3.9M in cash on the balance sheet.
Indaptus Therapeutics News
INDP FAQ
What was Indaptus Therapeutics, Inc.’s price range in the past 12 months?
Indaptus Therapeutics, Inc. lowest stock price was $2.48 and its highest was $58.25 in the past 12 months.
What is Indaptus Therapeutics, Inc.’s market cap?
Indaptus Therapeutics, Inc.’s market cap is $3.22M.
When is Indaptus Therapeutics, Inc.’s upcoming earnings report date?
Indaptus Therapeutics, Inc.’s upcoming earnings report date is Nov 18, 2025 which is in 69 days.
How were Indaptus Therapeutics, Inc.’s earnings last quarter?
Indaptus Therapeutics, Inc. released its earnings results on Aug 13, 2025. The company reported -$9.09 earnings per share for the quarter, beating the consensus estimate of -$9.24 by $0.15.
Is Indaptus Therapeutics, Inc. overvalued?
According to Wall Street analysts Indaptus Therapeutics, Inc.’s price is currently Undervalued.
Does Indaptus Therapeutics, Inc. pay dividends?
Indaptus Therapeutics, Inc. does not currently pay dividends.
What is Indaptus Therapeutics, Inc.’s EPS estimate?
Indaptus Therapeutics, Inc.’s EPS estimate is -4.17.
How many shares outstanding does Indaptus Therapeutics, Inc. have?
Indaptus Therapeutics, Inc. has 1,106,529 shares outstanding.
What happened to Indaptus Therapeutics, Inc.’s price movement after its last earnings report?
Indaptus Therapeutics, Inc. reported an EPS of -$9.09 in its last earnings report, beating expectations of -$9.24. Following the earnings report the stock price went up 2.427%.
Which hedge fund is a major shareholder of Indaptus Therapeutics, Inc.?
Currently, no hedge funds are holding shares in INDP
Company Description
Indaptus Therapeutics, Inc.
Indaptus Therapeutics (INDP) is a biotechnology company focused on developing innovative therapies for the treatment of serious diseases. The company specializes in leveraging its proprietary technologies to create novel drug candidates aimed at addressing unmet medical needs. Operating within the pharmaceutical and biotechnology sectors, Indaptus Therapeutics is dedicated to advancing its pipeline of therapeutic products through rigorous research and development processes.
INDP Stock 12 Month Forecast
Average Price Target
$25.00
▲(829.37% Upside)
Technical Analysis
Palisade Bio
―
Alaunos Therapeutics
―
Titan Pharmaceuticals
―
Xenetic Biosciences
―
Longevity Health Holdings
―
Ownership Overview
10.13% Insiders
2.09% Mutual Funds
1.32% Other Institutional Investors
84.86% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---